Hypoxia-Inducible Factor Activators in Renal Anemia: Current Clinical Experience.
Neil S Sanghani, Volker H Haase
https://pubmed.ncbi.nlm.nih.gov/31477256/Actively Recruiting
Led by Mansoura University · Updated on 2025-05-13
46
Participants Needed
1
Research Sites
2 weeks
Total Duration
Patients with kidney failure who need hemodialysis often face anemia, heart and blood vessel problems, and a condition called Malnutrition-Inflammation-Atherosclerosis MIA syndrome. This trial studies whether Roxadustat, a newer oral medication, works better than standard anemia treatments in improving anemia, heart health, and MIA syndrome. It is a randomized, open-label clinical trial comparing Roxadustat to conventional treatments over six months. Participants will be randomly assigned to one of two groups. One group will take oral Roxadustat three times per week, with doses adjusted based on hemoglobin levels, while stopping other anemia injections. The other group will continue their usual anemia treatment, typically involving injections and iron supplements. Both groups will receive standard care for other conditions during the six-month treatment period. Throughout the study, researchers will assess heart function using echocardiography and carotid ultrasound, measure markers of nutrition, inflammation, and anemia, and collect data at the start and after six months. Safety will be monitored continuously. The main outcome is the change in left ventricular ejection fraction, with additional measures including carotid artery thickness, inflammatory markers, and protein catabolic rate. The trial is sponsored by Mansoura University and participation lasts six months.
CONDITIONS
Roxadustat's Effect on Heart, Nutrition, and Inflammation in Hemodialysis Patients
I
Ibrahim M Galalah, MSC
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
Mansoura University
Lead Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 6 months
Participants receive assigned anemia management treatment for 6 months. The intervention group takes oral Roxadustat three times per week, while the control group continues conventional anemia therapy including erythropoiesis-stimulating agents and/or iron supplementation as per standard clinical practice. Safety monitoring occurs throughout this period.
Baseline visit and 1 follow-up visit at 6 months
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
2
Have more questions? Get in touch with our team for quick support
Neil S Sanghani, Volker H Haase
https://pubmed.ncbi.nlm.nih.gov/31477256/Desmond Y H Yap, Lawrence P McMahon, Chuan-Ming Hao...
https://pubmed.ncbi.nlm.nih.gov/33222343/Qiaoqiao Zhou, Mian Mao, Jing Li...
https://pubmed.ncbi.nlm.nih.gov/37489561/Mansoura University
Lead Sponsor